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Abstract
Background: Morinda citrifolia L. that was reported with immunomodulating and cytotoxic effects has been
traditionally used to treat multiple illnesses including cancer. An anthraquinone derived from fruits of Morinda
citrifolia L., nordamnacanthal, is a promising agent possessing several in vitro biological activities. However, the in
vivo anti-tumor effects and the safety profile of nordamnacanthal are yet to be evaluated.
Methods: In vitro cytotoxicity of nordamnacanthal was tested using MTT, cell cycle and Annexin V/PI assays on human
MCF-7 and MDA-MB231 breast cancer cells. Mice were orally fed with nordamnacanthal daily for 28 days for oral
subchronic toxicity study. Then, the in vivo anti-tumor effect was evaluated on 4T1 murine cancer cells-challenged mice.
Changes of tumor size and immune parameters were evaluated on the untreated and nordamnacanthal treated mice.
Results: Nordamnacanthal was found to possess cytotoxic effects on MDA-MB231, MCF-7 and 4T1 cells in vitro.
Moreover, based on the cell cycle and Annexin V results, nordamnacanthal managed to induce cell death in both
MDA-MB231 and MCF-7 cells. Additionally, no mortality, signs of toxicity and changes of serum liver profile were
observed in nordamnacanthal treated mice in the subchronic toxicity study. Furthermore, 50 mg/kg body weight
of nordamncanthal successfully delayed the progression of 4T1 tumors in Balb/C mice after 28 days of treatment.
Treatment with nordamnacanthal was also able to increase tumor immunity as evidenced by the
immunophenotyping of the spleen and YAC-1 cytotoxicity assays.
Conclusion: Nordamnacanthal managed to inhibit the growth and induce cell death in MDA-MB231 and MCF-7
cell lines in vitro and cease the tumor progression of 4T1 cells in vivo. Overall, nordamnacanthal holds interesting
anti-cancer properties that can be further explored.
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Background
Breast cancer is the leading cause of cancer-related deaths
in women today. In Malaysia, the number of cases of
women being diagnosed with breast cancer has risen
alarmingly, similar to the global trend [1]. Breast cancer
can be classified as non-invasive breast cancer and invasive
breast cancer. Recent advances in cancer genomics map-
ping has helped to classify breast cancer based on the
expression of cellular receptors, which are estrogen recep-
tor (ER), progesterone receptor, and anti-human epidermal
growth factor receptor 2 (HER2) [2]. Various treatments
have been used to treat breast cancer including surgery,
chemotherapy and radiation [3]. Nevertheless, the number
of successful treatments is still limited, mainly due to the
severe side effects produced by the treatment [4]. Most of
the drugs given to treat breast cancer, or any kind of can-
cer, may induce unwanted toxic effects. Among different
types of breast cancer classified by the expression of ER,
PR and ER, triple-negative breast cancer (TNBC) which
lacks the expression of all the above cellular receptors is
the highly metastatic stage IV breast cancer [2]. The ability
of the cells to invade other sites of the body is the main
contributor to the number of cancer-associated fatalities
[1]. Current research is still attempting to discover better
treatment against this advance stage of breast cancer [5].
An ideal treatment would not only inhibit the growth of
the cells but also obstruct the metastasis process and
enhance the immune system as well. Among the available
cell lines, 4T1 cell line has been widely used as a model for
in vitro and in vivo study of TNBC [5].
Over the decades, much effort has been directed to using
naturally derived molecules as a source of anti-cancer
agents [6, 7]. Natural sources have been proven to provide
a large database for the search of new drugs [6, 7]. In fact,
some of the most remarkable drugs currently used were
derived from various natural products including doxorubi-
cin, taxol and curcumin [7]. Morinda citrifolia can be
found in different parts of the world mainly Borneo,
Indonesia, Malaysia and some parts of Australia [8, 9].
This plant is part of the Rubiaceae family and can be
physically identified as having large, green, shiny leaves [8,
9]. In Malaysia, the fruits of Morinda citrifolia are known
as mengkudu or noni [8]. Mengkudu is commonly eaten
raw or can be used in various local dishes as garnish. Trad-
itionally, the fruits can be turned into juices and be used to
treat various illnesses including diabetes and inflammation
[10, 11]. In fact, in traditional Chinese medicine, the fruits
have been used to treat abdominal pain and menstrual-
related diseases [9]. In Hawaii, the roots and barks of
Morinda citrifolia is traditionally used as dyes [12]. More-
over, besides the leaves and fruits, the roots and barks of
this plant are also traditionally used to treat inflammation
or infections [12]. There are various bioactive molecules
that can be extracted from the stems and roots of the plant
but the most notable ones are damnacanthal and nordam-
nacanthal [13]. Nordamnacanthal is an anthroquinone that
can be found in the stems and roots of Morinda citrifolia
[14]. The bioactivities of nordamnacanthal have been
reported but are very preliminary. These reports claim that
nordamnacanthal possess anti-viral, anti-microbial and
cytotoxic effects [14–16]. The toxicity as well as the effect-
iveness of nordamnacanthal as an anti-cancer agent in an
in vivo setting has not been reported yet. Therefore, this
study aims to evaluate the toxicity of nordamncanthal as
well as the ability of the compound to inhibit cancer pro-
gression in both in vitro and in vivo breast cancer settings.
Methods
Isolation of Nordamnacanthal
Morinda citrifolia L. was collected from Kg. Tanjung
Keramat, Langkap, Perak, Malaysia. The plant was formally
identified by Prof. Dr. Nor Hadiani Ismail (UiTM,
Malaysia). Voucher specimen (ATCL 0012) was deposited
for future evidence in the herbarium collection. Nordam-
nacanthal (NDAM) (Fig. 1) was isolated from the root of
M. citrifolia L. by solvent fractionation. The compound
was then purified using high performance liquid chroma-
tography method and characterized as reported in the
previous publication [17].
Cell culture and maintenance
MCF-7, MDA-MB231 and 4T1 cells were obtained from
the American Tissue Culture Collection (ATCC,
Manassas, USA). Both MCF-7 and 4T1 cells were main-
tained in RPMI-1640 medium (Sigma-Aldrich, St. Louis,
USA) while MDA-MB231 cells were cultured in DMEM
medium (Sigma-Aldrich, St. Louis, USA). Both media were
supplemented with 10% fetal bovine serum (Cat number:
16,000,044; US origin, Standard Sterile-Filtered; Endotoxin
level < 5 EU/mL; Hemoglobin level < 10 mg/dl) (Gib-
co,Thermo Fisher Scientific, Waltham, USA) and 1%
penicillin-streptomycin (Gibco, Thermo Fisher Scientific,
Waltham, USA). All of the cells were maintained in a 37 °
C humidified CO2 incubator equipped with 5% CO2.
Fig. 1 Molecular structure of Nordamnacanthal
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In vitro MTT and trypan blue cell viability assays
MCF-7, MDA-MB231 and 4T1 cells were seeded in
96-well plates at the density of 0.8 × 104 cells/well and
were left to incubate for 24 h. Seeding of 4T1 cell in 96
well plates were based on the optimization for the cell
confluency, where 4T1 cells reached 70% of confluency at
24 h and 95% of confluency at 72 h (results not shown).
The following day, various concentrations of NDAM were
administered to the cells ranging from 30 μg/mL to
3.75 μg/mL with 2 fold serial dilution for MTT assay and
trypan blue cell counting. The cells were incubated for
72 h before assessing the viability of the cells.
After the designated incubation time, 20 μl of MTT so-
lution (5 mg/mL) (Calbiochem, Merck Millipore, Billerica,
USA) was added to each of the wells and the plates were
further incubated for an additional 4 h. Next, the medium
as well as the MTT solution were removed from the wells,
and 100 μL of DMSO was added to solubilize the resulting
crystals. Lastly, the absorbance of each of the wells was
measured using a microplate reader (Biotek Instruments,
Winooski, USA) at 570 nm. The percentage of viability
was calculated based on the formula below:
Percentage of cell viability (%) = OD Treated/OD
Control × 100%.
For trypan blue cell counting, cells were harvested after
72 h of incubation and counted under inverted light
microscope (Nikon, Minato, Japan) using hemocytometer
(Sigma-Aldrich, St. Louis, USA). The percentage of viabil-
ity was calculated based on the formula below:
Percentage of cell viability (%) = NDAM treated cell
number/untreated cell number × 100%.
In vitro flow cytometry analyses of cell death (cell cycle
and Annexin V)
MCF-7 and MDA-MB231 cells were seeded in 6-well
plates at the density of 2.4 × 105 cells/well. The following
day, the cells were treated with 10 μg/mL of NDAM for
48 h. After the incubation period, the cells were
harvested and subjected to two flow cytometry analysis:
Annexin V assay and cell cycle assay. For the Annexin V
assay, according to the manufacturer’s protocol (Becton
Dickinson, Franklin lakes, USA), the cells were stained
with 5 μl of Annexin V-FITC and 5 μl of Propidium
Iodide (PI) in 100 μl of 1X Annexin Binding buffer for
15 min. Cell cycle assay was performed using BD cell
cycle kit (Becton Dickinson, Franklin lakes, USA)
according to the manufacturer’s protocol.In brief, the
cells were washed with 1X washing buffer three times,
before adding solution 1, solution 2 and solution 3 inter-
mittently. For AnnexinV-FITC/PI assay, all samples were
analyzed by FACS Calibur flow cytometer system (Bec-
ton Dickinson, Franklin lakes, USA) with BD CellQuest
Pro software (Becton Dickinson, Franklin lakes, USA)
using four parameters (FSC, SSC, FITC and PE
fluorescence). Untreated MCF-7 and MDA-MB231 cells
without Annexin V-FITC and PI staining were used as
the negative control for gating of auto-fluorescent signal.
NDAM (10 μg/mL) treated MCF-7 and MDA-MB231
cells were stained with either Annexin V-FITC or PI and
run independently for gating of Annexin V+ and PI+ cell
population. In terms of cell cycle, all samples were ana-
lyzed using FACS Calibur flow cytometer system (Becton
Dickinson, Franklin lakes, USA) with BD CellQuest Pro
software (Becton Dickinson, Franklin lakes, USA) using
three parameters (FSC, SSC and PI fluorescence).
Untreated MCF7 and MDA-MB231 cells were used for
gating of G1, S and G2 cell cycle phases based on the
intensity of the red PI fluorescent. For both assays,
approximately 10,000 events were collected for each
samples based on the optimized gating procedures as
described above.
Animal ethics approval
All studies involving animals were conducted in compli-
ance with the Universiti Putra Malaysia’s ethical guide-
lines as approved by the Animal Ethics Committee
(Universiti Putra Malaysia, Malaysia). The approval
number obtained: UPM/IACUC/AUP-R098/2014.
In vivo subchronic toxicity study
Subchronic toxicity study was performed using 8-weeks
old, male BALB/c mice that were obtained from the ani-
mal house, Monash University, Malaysia (Subang Jaya,
Malaysia). The mice were randomly selected and grouped
into 5 mice per group; control group, low dose nordamna-
canthal (LD NDAM) group and high dose (HD NDAM)
group. All of the mice were kept at 25 ± 2 °C on a regular
12-h dark-light cycle and were fed with tap water and
standard diet pellets. The experiment began 1 week after
obtaining the mice, allowing the mice to adapt to the
laboratory environment. The mice were housed in stand-
ard polypropylene cages sized 7 × 10 inches, with 4-5 mice
per cage. The treatment of 10 mg/kg/day of NDAM for
the low dose nordamncanthal (LD NDAM) group and
50 mg/kg/day for the high dose (HD NDAM) groupwere
administered orally for 28 days. The treatments were
administered consistently at 11 am every day. Toxicity
signs such as shedding of fur, loss of appetite and erratic
behavior were observed daily if there are any. At the end
of the 28 days of experimental period, all mice were anes-
thetized with isoflurane (Sigma-Aldrich, St. Louis, USA),
and euthanized by cervical dislocation.
Serum biochemical analysis
Blood was obtained from the sacrificed mice by cardiac
puncture and the serum was obtained by centrifugation.
Next, the serum was subjected to biochemical analysis.
The level of aspartate aminotransferase (AST), alanine
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aminotransferase (ALT), alkaline phosphatase (ALP),
creatinine, and albumin, in mice serum were determined
by standard assay kits (Roche Diagnostic GmbH, Indian-
apolis, USA) and analyzed using 902 Hitachi automatic
analyser (Hitachi LTD, Chiyoda, Japan).
In vivo study of the antitumor effect of NDAM using
4T1-bearing BALB/C mice
For the in vivo study of the antitumor effect of NDAM,
8-weeks old, female BALB/C mice were obtained from
animal house of Monash University Malaysia (Subang
Jaya, Malaysia). The mice were acclimatized to the
laboratory environment for 1 week before commencing
the experiment. Around 1 × 105 of 4T1 cells were inocu-
lated in the mice subcutaneously and then, the mice
were randomly divided into two groups; control and
NDAM groups with each group bearing 6 mice.
Tumours were measured using a caliper and the tumour
volumes were calculated using the formula V = 1/2
(width2× length).For the treatment, 50 mg/kg of NDAM
was administered orally to the mice from day 5 when
the tumor volume reach around 0.5mm3 until day 28.
After the designated treatment time, all mice were anes-
thetized with isoflurane (Sigma-Aldrich, St. Louis, USA),
and euthanized by cervical dislocation The organs were
harvested for further analyses.
Immunophenotyping analysis of CD3, CD4 and
CD8-stained splenocytes
Spleens harvested from mice from each groups were
mechanically disrupt by meshing the organs using 70
μmeter cell strainer. The cells were then washed with
ice-cold PBS twice before being subjected to lysis buffer
for 15 min to remove red blood cells. Subsequently, the
cells were washed with PBS again before being stained
with anti-CD3-FITC [UCHT1] with anti-CD4-PE
[74-12-4] or anti-CD3-FITC [UCHT1] with anti-CD8-
PerCP [MEM-31] antibodies (Abcam, Cambridge, UK;
Catalog No: ab34275, ab25408, ab65949).The cells were
incubated for 2 h at 4 °C before being fixed in 4% para-
formaldehyde. On the next day, the stained cells were
washed and run by FACS Calibur flow cytometer system
(Becton Dickinson, Franklin lakes, USA) with BD
CellQuest Pro software (Becton Dickinson, Franklin
lakes, USA) using five parameters (FSC, SSC, FITC, PE
and PerCP fluorescence). Splenocytes from untreated
4T1-mice stained with isotype-control IgG (Abcam,
Cambridge, UK; Catalog no: ab37355) was used for the
gating of auto-fluorescent signal. Splenocytes from
NDAM treated 4T1-mice was stained with single anti-
body of either anti-CD3-FITC, anti-CD4-PE or anti-
CD8-PerCP for establishment of gating of the double
staining. Above compensation was used to run the sple-
nocytes from untreated 4T1-mice and NDAM treated
4T1-mice and approximately 10,000 events were col-
lected for each samples based on the optimized gating
procedures as described above.
Cytokine analysis of IL-2, IL-4 and IFN-γ
Cytokine analysis of IL-2, IL-4 and IFN-γ in the serum
of the untreated and NDAM-treated 4T1-mice was per-
formed using the ELISA IL-2, IL-4 and IFN-γ MAX™ kit
(Biolegend, San Diego, USA). Samples from normal mice
treated with nordamnacanthal (50 mg/kg body weight)
was collected from the female mice via tail vein sam-
pling at day 28 of feeding with 50 mg/kg body weight of
nordamnacanthal from subchronic toxicity test. Briefly,
antibodies for IL-2, IL-4 and IFN-γ were fixed in the
wells of 96-well plates overnight. The following day, after
series of washing and blocking, samples were incubated
in the plates for 2 h. Subsequently, the wells were then
stained and measured colorimetrically using a micro-
plate reader (Biotek Instruments, Winooski, USA). The
value of absorbance of each sample was calculated
against the respective control.
Ex vivo splenocytes and YAC-1 co-culture analysis
Spleens harvested from mice from each groups were
mechanically disrupt by meshing the organs using 70
μmeter cell strainer (Becton Dickinson, Franklin lakes,
USA). The cells were then washed with ice-cold PBS
(Sigma-Aldrich, St. Louis, USA) twice before being
subjected to lysis buffer for 15 min to remove red blood
cells. The splenocytes were counted and were seeded
together with YAC-1 cells at a ratio of 1 to 5 and 1 to
10. After 24 h, the cytotoxicity was evaluated using the
CytoTox 96 nonradioactive cytotoxicity assay kit
(Promega, Madison,USA) according to the manufac-
turer’s protocol.
Statistical analysis
In vitro experiments were carried out with 3 independent
experiments and each of the experiment consisted of at
least 3 biological replicates. In vivo experiment was
assayed on all 6 mice and each with 3 technical replicates.
All results are expressed as Mean ± Standard Deviation
(S.D.). Significant levels (p < 0.05) were evaluated using
ANOVA test (one way) followed by post hoc Duncan test.
Results
NDAM inhibited the proliferation and induced apoptosis
in MCF-7, MDA-MB231 and 4T1 cells in vitro
The MTT assay was carried out as a preliminary testing of
the cytotoxic effects of NDAM on various cancer cell lines.
Based on both MTT assay (Fig. 2a) and Trypan blue cell
counting (Fig. 2b), NDAM managed to reduce the viability
of MCF-7,MDA-MB231 and 4T1 cells in a dose-
dependent manner as higher concentration of NDAM
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reduced higher degree of the viability for all the tested
breast cancer cells. In the MTT assay, the IC50 value of
NDAM on MDA-MB231 and 4T1 cells was almost similar,
around 12.5 ± 4.2 μg/mL. Meanwhile, the IC50 value for
MCF-7 cells was around 11.0 ± 4.7 μg/mL (Fig. 2a). When
tested with Trypan blue cell counting, IC50 values of
NDAM on MCF-7, MDA-MB231 and 4T1 were slightly
lower than MTT assay with 8.0 ± 1.2 μg/mL, 10.0 ± 0.8 μg/
mL, 11.0 ± 1.0 μg/mL, respectively. No IC50 value was
obtained on normal breast cells MCF10A treated with
NDAM in both MTT assay and trypan blue cell counting.
Furthermore, additional assays were carried out to eluci-
date the mechanism of cell death triggered by NDAM.
Based on the Annexin V assay in Fig. 4, NDAM increased
the population of early apoptosis and late apoptosis cells in
both MCF-7 and MDA-MB231 as compared to the control
after 48 h of treatment. Additionally, the profile of cell
cycle analysis also exhibited the same pattern. The number
of cell population at the Sub G0/G1 phase increased
significantly in the NDAM-treated cells for both MCF-7
and MDA-MB231 cells as shown in Fig. 3.
NDAM did not induce any toxic effects in the in vivo
subchronic toxicity study
Based on Table 1, NDAM did not cause any deaths in
the mice after 28 days of treatment with two different
doses of treatment. Moreover, there were no apparent
toxic signs observed and no significant changes to the
body weight of the mice tested. Biochemical analysis of
important organ markers were also tested in the serum
of the mice tested. After 28 days, there were no signifi-
cant changes to the values of ALT, AST and ALP levels
comparing to the untreated control.
NDAM reduced the 4T1 tumor size and weight
After 28 days of treatment with 50 mg/kg of NDAM in
female BALB/C mice, the mice were sacrificed and the
tumors and organs were harvested. In the duration of
the treatment, no mortalities were observed, all of the
mice survived until the end of the experiment. In
addition, no significant body weight changes were
observed between control and NDAM treated 4T1-mice
within 28 days of study period (Fig. 4c). Tumors were
harvested from both the control and NDAM-treated
4T1 group were weighed and measured individually. As
shown in Fig. 4a the average volume of the tumors from
the NDAM-treated 4T1-mice were smaller in relative to
the control group throughout the experiment. The same
pattern can also be observed in the weight of the
harvested tumors as displayed in Fig. 4b.
NDAM regulated several immune markers in
tumor-bearing mice
The level of T cells was measured in the splenocytes of
the control and NDAM-treated 4T1-mice via immuno-
phenotyping. As in Fig. 5, the level of CD4/CD3 cells
was increased in NDAM-treated 4 T1-mice as compared
to the control mice. Similarly, the level of CD8/CD3
cells was also elevated in the NDAM-treated 4T1-mice
than the untreated mice. Additionally, there was no
significant difference in the level of NK1.1/CD3 cells
between the NDAM-treated 4T1-mice and the control
mice. Nevertheless, based on the cytotoxicity results of
splenocytes against YAC-1 cells, NDAM-treated spleno-
cytes had a higher percentage of toxicity using both 1:10
and 1:5 ratios as in Fig. 6. Moreover, in the serum of the
NDAM-treated 4T1-mice, the concentration of IL-2 and
IFN-γ were significantly higher than the untreated mice
(Fig. 7). On the other hand, level of serum IL-4 was
lower in NDAM-treated 4T1-mice. The IL-2, IL-4 and
IFN-γ of the NDAM-treated 4T1-mice are similar with
the healthy control and healthy NDAM mice without
significant changes (Fig. 7).
Fig. 2 Percentage of viable cells against different concentrations of NDAM in MCF-7, MDA-MB231, 4T1 and MCF-10A cells after 72 h of treatment
quantified by (a) MTT assay and (b) Trypan blue cell counting
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Discussion
Morinda citrifolia is a well-known plant that possesses
various promising bioactivities. A notable anthraquin-
one, damncanthal, which can be extracted from this
plant has been known to be involved in several anti-
cancer mechanisms. A lesser known anthraquinone is
the NDAM, which can also be extracted from the stems
of Morinda citrifolia. Anthraquinones are an interesting
set of molecules that can either be synthetically pro-
duced or found in nature naturally. This set of molecules
is known to be used in several applications namely; anti-
malarial drugs, anti-neoplastic drugs and colorants in
food, textile and cosmetics [18, 19]. Anthraquinones
have immensely contributed to the development of
effective anti-cancer drugs [20]. NDAM has been
reported to be cytotoxic to several cancer cell lines
Fig. 3 Cell cycle analysis and Annexin V analysis in MCF-7 and MDA-MB231 cells after treatment with 10 μg/mL of NDAM for 48 h. Values represent
the mean with standard deviation. *Significance set at p < 0.05
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based on the MTT assay [14–16]. Herein, NDAM was
shown to be cytotoxic to all three breast cancer cell
lines, MCF-7, MDA-MB231 and 4T1 cells. It has been
reported that NDAM also inhibited the proliferation of
several other cancer cell lines such as HL-60, CEM-SS,
WEHI-3B and K562 [14, 15]. Nevertheless, the IC50
values of NDAM in MCF-7 and MDA-MB231 were
much lower than the other reported cell lines. The
effects on MCF-7 and MDA-MB231 were similar despite
the differences between the two cell lines. NDAM man-
aged to induce apoptosis in both cell lines as evidenced
by the Annexin V and cell cycle analysis. The
externalization of phosphatidylserine is a vital parameter
in cells undergoing apoptosis and has been used to
support the induction of apoptosis by using Annexin V-
based assays [21]. Furthermore, the deregulation of the
cell cycle process is also an imperative step in the execu-
tion of apoptosis [22, 23]. Inhibition of cell proliferation
could tilt the balance between cell survival and cell
death and eventually trigger tumor regression [22].
Damnacanthal, a similar molecule to NDAM also
exhibited striking anti-tumorigenesis effects in vitro by
inducing apoptosis in several different cancer cell lines.
Though damnacanthal has a much lower IC50 value in
MCF-7 and MDA-MB231 than NDAM, damnacanthal
has been reported to be less selective in non-
transformed mammary cell line, MCF-10A [24].
Though anthraquinones have a wide range of applica-
tions, there is still concern regarding the safety of
anthraquinones especially for human consumption [19].
Therefore, it is important to measure the toxicity of
NDAM before applying it for other purposes. Ideally, a
safe sample would not induce any mortality, toxic signs
or severe body weight changes to the subjects tested.
Besides that, the levels of ALT, ALP and AST are also
important indicators for hepatic injury. Leakage of these
proteins in the blood could indicate damage to hepato-
cytes such as loss of membrane integrity and mitochon-
drial damage and could serve as a sign of toxicity [25].
NDAM was shown to not be toxic on the mice tested
after 28 days based on the physical appearance of the
mice and the levels of AST, ALT and ALP.
The efficacy of a treatment in vitro cannot be directly
translated into a more complex setting. As NDAM did
not induce any sub-chronic toxicity, in vivo antitumor
study using 4T1 cells was further conducted. Inoculation
of 4T1 cells in mice is a well-established method for in
vivo models of breast cancer. The size and weight of the
tumors are basic representation of the effectiveness of the
treatment administered. Logically, a specific treatment
should reduce the size and weight of the harvested tumors
as compared to the control. Additionally, the effect be-
tween immune markers and cancer progression is greatly
linked. A healthy and active immune system could
Table 1 Evaluation of the sub-chronic toxicity of NDAM in BALB/C mice
Mortality Body weight (g) Day 0 Body weight (g) Day 28 Body weight (g) Day 60 Toxic Signs ALT (U/L) AST (U/L) ALP (U/L)
Control None 20.30 ± 1.10 23.10 ± 1.70 25.60 ± 1.80 None 75.6 ± 34.0 301.5 ± 53.0 101.7 ± 13.0
LDNDAM
(10 mg/
kg)
None 19.86 ± 1.30 23.85 ± 1.90 25.80 ± 1.70 None 69.4 ± 39.0 316.0 ± 37.0 125.4 ± 20.4
HDNDAM
(50 mg/
kg)
None 20.80 ± 1.40 22.50 ± 2.10 24.90 ± 2.30 None 64.5 ± 32.0 246.0 ± 55.0 113.7 ± 19.0
Parameters evaluated for sub-chronic toxicity test including mortality rates, body weight, toxic signs and biochemical analysis of ALT, AST and ALP
No statistically significant was observed compared to control (p < 0.05)
Fig. 4 a Tumor volume; b tumor weight and (c) body weight of control and NDAM-treated 4T1-mice after 28 days of treatment. Values represent
the mean with standard deviation. *Significance set at p < 0.05
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Fig. 5 Percentage of the immunophenotyping results of the spleens harvested from the control and NDAM-treated 4T1-mice. Values represent
the mean with standard deviation. *Significance set at p < 0.05
Fig. 6 Cytotoxicity values for the co-culture of splenocytes and YAC-1 cells.Values represent the mean with standard deviation. *Significance set at p< 0.05
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enhance the anti-cancer treatment and thus reducing the
progression of cancer [26]. NDAM managed to enhance
the percentage of CD8/CD3 and NK cells as evidenced by
the immunophenotyping and cytotoxicity against YAC
cells. Both cytotoxic T cells and NK cells defend the host
by lysing tumor cells upon recognition [26–28]. Cytotoxic
T cells is known to induce cell death via granzyme B-me-
diated apoptosis [29]. Additionally, CD4/CD3 population
and Type 1 T helper (Th1) associated cytokines including
IL-2 and IFN- γ were also increased upon NDAM treat-
ment. On the other hand, level of IL-4, a type 2 T helper
(Th2) associated cytokine was found reduced in the
NDAM-treated 4T1 mice. These results indicated that
NDAM treatment increased Th1/Th2 ratio. Th1 cells
function by maintaining the activity of T cytotoxic cells
and memory of the immune system [30]. Moreover, Th1
cells are able to recruit several other important immune
players such as mast cells and macrophages [30]. Activa-
tion of Th1 and Th1 associated cytokines including IFN-γ
and IL-2contribute to the host’s defense mechanism
against cancer [30–32].
Conclusion
Despite the progress in cancer research, the search for
viable anti-cancer drug is still on the rise. NDAM, an
anthroquinone that can be found in the stems of
Morinda citrifolia is a promising compound that pos-
sessed remarkable anti-cancer properties. Based on this
pilot in vivo study, NDAM was not toxic in the animals
tested. Moreover, nordamnacanthal managed to reduce
the viability of two breast cancer cells, MCF-7 and
MDA-MB231 in vitro. NDAM successfully decreased
the size of the 4T1 tumors in vivo and increased the
population of T helper, cytotoxic T, and NK cells.
Further studies using larger sample size and different
models of antitumor studies can further support the
potential of NDAM for treatment of breast cancer.
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